Cited 34 times in
Comparison of the 2022 ACR/EULAR Classification Criteria for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Previous Criteria
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박용범 | - |
dc.contributor.author | 이상원 | - |
dc.contributor.author | 표정윤 | - |
dc.date.accessioned | 2023-03-22T02:09:17Z | - |
dc.date.available | 2023-03-22T02:09:17Z | - |
dc.date.issued | 2023-01 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/193538 | - |
dc.description.abstract | Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) comprises group of small vessel vasculitides, including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). In 2022, the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) jointly proposed new classification criteria for AAV (the 2022 ACR/EULAR criteria). In this review, we briefly summarize the 2022 ACR/EULAR criteria for GPA, MPA, and EGPA, and introduce our clinical experience with applying them to patients who were previously diagnosed with AAV based on three criteria: firstly, the classification criteria for GPA and EGPA proposed by the ACR in 1990; secondly, the algorithm for the classification of AAV and polyarteritis nodosa proposed by the European Medicines Agency algorithm in 2007 (the 2007 EMA algorithm); and thirdly, the revised International Chapel Hill Consensus Conference nomenclature of vasculitides in 2012 (the 2012 CHCC definitions). We found that concordance rate was highest in patients with MPA (96.6%), followed by those with EGPA (86.3%) and GPA (73.8%). In addition, compared to previous criteria, we noted several issues of the undervalued or overvalued items in the 2022 ACR/EULAR criteria for classifying AAV and provided several suggestions. To increase the diagnostic accuracy and reduce the discordance rate among the new and previous criteria for AAV, we suggest that the previous criteria should be considered together with the 2022 ACR/EULAR criteria when applying the classification criteria for AAV to patients suspected of AAV. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Yonsei University | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* | - |
dc.subject.MESH | Antibodies, Antineutrophil Cytoplasmic | - |
dc.subject.MESH | Churg-Strauss Syndrome* / diagnosis | - |
dc.subject.MESH | Granulomatosis with Polyangiitis* / diagnosis | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Microscopic Polyangiitis* / diagnosis | - |
dc.subject.MESH | Rheumatology* | - |
dc.subject.MESH | United States | - |
dc.title | Comparison of the 2022 ACR/EULAR Classification Criteria for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Previous Criteria | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jung Yoon Pyo | - |
dc.contributor.googleauthor | Lucy Eunju Lee | - |
dc.contributor.googleauthor | Yong-Beom Park | - |
dc.contributor.googleauthor | Sang-Won Lee | - |
dc.identifier.doi | 10.3349/ymj.2022.0435 | - |
dc.contributor.localId | A01579 | - |
dc.contributor.localId | A02824 | - |
dc.contributor.localId | A04244 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 36579374 | - |
dc.subject.keyword | 2022 | - |
dc.subject.keyword | ACR/EULAR | - |
dc.subject.keyword | Antineutrophil cytoplasmic antibody-associated vasculitis | - |
dc.subject.keyword | classification criteria | - |
dc.contributor.alternativeName | Park, Yong Beom | - |
dc.contributor.affiliatedAuthor | 박용범 | - |
dc.contributor.affiliatedAuthor | 이상원 | - |
dc.contributor.affiliatedAuthor | 표정윤 | - |
dc.citation.volume | 64 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 11 | - |
dc.citation.endPage | 17 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.64(1) : 11-17, 2023-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.